Information Provided By:
Fly News Breaks for June 16, 2016
BMRN
Jun 16, 2016 | 10:54 EDT
Evercore ISI analyst Mark Shoenbaum is the forth analyst this morning to defend BioMarin and say the suspension of the gene study in severe hemophilia A patients is not new and that the posting of the update on ClinicalTrials.gov just took a few weeks. Shoenbaum said BioMarin confirmed that they are in the discussions with EU regulators, but they have not been finalized and reiterated prior communications regarding dosing the final 3 patients by August and sharing the full 16 week data for all 12 patients by year-end.
News For BMRN From the Last 2 Days
There are no results for your query BMRN